until at least 2032, when the first main patent for the drug, held by Novo Nordisk,expires
Here's what to know about the peptides under discussion this week: Thursday's votes: FDA advisers largely vote in favor of reclassifying BPC-157: The votes came in 8-6, with one abstention, in favor of reclassifying BPC-157, both in free-base and acetate form
Heat, moisture, oxygen exposure, light, and repeated warming can still reduce quality over time
Very likely hundreds of thousands, perhaps even now into the millions, but we actually have essentially no human data as to how BPC-157 works in humans and why it does seem, because this seems to be the quote-unquote anecdata, to accelerate healing of a variety of different injuries
Any recommendation by the panel would be advisory and not binding on the agency
1995 Sep;2(4):357-62